• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 14D9/A filed by LAVA Therapeutics N.V.

    9/3/25 5:22:27 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LVTX alert in real time by email
    SC 14D9/A 1 tm2523908d3_sc14d9a.htm SC 14D9/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14D-9

     

    Solicitation/Recommendation Statement

    Under Section 14(d)(4) of the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

     

    LAVA Therapeutics N.V.

    (Name of Subject Company)

     

     

     

    LAVA Therapeutics N.V.

    (Name of Persons Filing Statement)

     

     

     

    Common shares, nominal value €0.12 per share

    (Title of Class of Securities)

     

    N51517105

    (CUSIP Number of Class of Securities)

     

    Stephen Hurly

    Chief Executive Officer and President

    LAVA Therapeutics, N.V.

    Yalelaan 62

    3584 CM Utrecht, The Netherlands

    +31 85 016 3100

    (Name, address, and telephone number of person authorized to receive notices and communications

    on behalf of the persons filing statement)

     

    With a copy to:

     

    Divakar Gupta

    Katie Kazem

    Courtney T. Thorne

    Rita Sobral

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    (212) 479-6000

     

     

     

    ¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

     

     

     

     

     

    This Amendment No. 1 (“Amendment No.1”) to Schedule 14D-9 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 previously filed by LAVA Therapeutics, N.V., a Dutch public limited liability company (naamloze vennootschap) (“LAVA” or the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on August 15, 2025 (together with any exhibits attached thereto, as it may be amended or supplemented from time to time, the “Schedule 14D-9”), with respect to the tender offer made by XOMA Royalty Corporation, a Nevada corporation (“Buyer”), to acquire all of the outstanding common shares, nominal value €0.12 per share, of LAVA (the “Shares”) for (i) a price per Share of $1.16 (the “Base Price Per Share”) plus an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Purchase Agreement, the “Additional Price Per Share” and together with the Base Price Per Share, the “Cash Amount”) plus (ii) one contingent value right (“CVR”) per Share, which shall represent the right to receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement, payable subject to any applicable tax withholding and without interest (together with the Cash Amount, the “Offer Consideration”), all upon the terms and subject to the conditions as set forth in the Offer to Purchase, dated August 15, 2025 (together with any amendments and supplements thereto, the “Offer to Purchase”), and in the related Letter of Transmittal (together with any amendments and supplements thereto, the “Letter of Transmittal” and together with the Offer to Purchase, the “Offer”). Any capitalized term used and not otherwise defined herein shall have the meaning ascribed to such term in the Schedule 14D-9.

     

    This Amendment No. 1 is being filed to reflect certain updates to the Schedule 14D-9 as set forth below. Unless stated otherwise, new text is reflected in bolded and underlined text, and any deleted text is bolded and denoted with a strikethrough. Except as set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference as relevant to the items in this Amendment No. 1.

     

    ITEM 3. PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS

     

    Item 3 of the Schedule 14D-9 is hereby amended and supplemented as follows:

     

    The second paragraph on page 2 of the Schedule 14D-9 is amended and supplemented as follows:

     

    The Offer is conditioned upon the satisfaction or waiver of certain customary conditions, including, among others: (i) that there have been validly tendered pursuant to the Offer, and not properly withdrawn (excluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been delivered in settlement or satisfaction of such guarantee prior to the Expiration Time), a number of Shares that, together with the Shares then owned by Buyer or its affiliates, represents at least 80% of LAVA’s issued and outstanding share capital (geplaatst en uitstaand kapitaal) immediately prior to the Expiration Time (the “Minimum Condition”), provided that the Minimum Condition may be reduced to 75% in certain circumstances specified in the Purchase Agreement and described on page 4 below; (ii) that there is not in effect any applicable law or order (whether temporary, preliminary or permanent) entered, enacted, promulgated, enforced, or issued by any court or other governmental authority of competent jurisdiction prohibiting, rendering illegal, or enjoining the consummation of the transactions contemplated by the Purchase Agreement (the “Transactions”); (iii) the accuracy of representations and warranties made by LAVA in the Purchase Agreement, including that, since the date of the Purchase Agreement, there shall not have occurred any Company Material Adverse Effect (as defined in the Purchase Agreement); (iv) compliance in all material respects by LAVA with its obligations under the Purchase Agreement; (v) that no effect, event, fact, change, development or occurrence has occurred following the date of the Purchase Agreement that has had or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect; (vi) that at the extraordinary general meeting (or a subsequent extraordinary general meeting) of LAVA shareholders, the LAVA shareholders have adopted resolutions related to appointment of Buyer’s designees to the LAVA Board (as defined below) and certain transactions pursuant to the Purchase Agreement; (vii) the Closing Net Cash (as defined in the Purchase Agreement) shall be no less than the amount specified in the Purchase Agreement; and (viii) no termination of the Purchase Agreement (each individually, an “Offer Condition,” and collectively, the “Offer Conditions”). The obligations of Buyer to consummate the Offer under the Purchase Agreement are not subject to a financing condition. A copy of the Purchase Agreement is filed as Exhibit (e)(1) to this Schedule 14D-9 and is incorporated herein by reference.

     

    Adding a new paragraph as the second paragraph of page 4, as follows:

     

    Notwithstanding any other term of the Offer or the Purchase Agreement, Buyer shall not be required to accept for payment or, subject to any applicable rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act (relating to Buyer’s obligation to pay for or return tendered Shares promptly after the termination or withdrawal of the Offer), pay for any Shares tendered pursuant to the Offer or during the Subsequent Offering Period (and not theretofore accepted for payment or paid for) unless there shall have been validly tendered in the Offer (and not properly withdrawn) prior to the expiration of the Offer that number of Shares that, represent at least the Minimum Condition; provided that that if (i) all of the Offer Conditions other than the Minimum Condition have been satisfied or waived in accordance with the Purchase Agreement, and (ii) Buyer has extended the Offer on three (3) or more occasions in consecutive periods of ten (10) Business Days each in accordance with the Purchase Agreement, then in such case Buyer may, its sole discretion, reduce the Minimum Condition from 80% to 75%.

     

    I-1

     

     

    The first paragraph under the heading entitled “Form of Tender and Support Agreement” on page 7 of the Schedule 14D-9 is amended and supplemented as follows:

     

    In connection with the execution of the Purchase Agreement, on August 3, 2025, following approval thereof by the LAVA Board, Buyer entered into tender and support agreements (each, a “Support Agreement”) with Stephen Hurly, Jay Backstrom, Kapil Dhingra, Amy Garabedian, Peter Kiener, Charles Morris, James Noble, Christy Oliger, Fred Powell, Mary Wadlinger, and Karen Wilson, who collectively comprise all of the Company’s executive officers and directors (collectively, the “Support Agreement Parties”). The Support Agreements provide that, among other things, the Support Agreement Parties irrevocably tender the Shares held by them in the Offer, upon the terms and subject to the conditions of such agreements. The Shares subject to the Support Agreements comprise approximately 0.5% of the outstanding Shares as of August 3, 2025. The Support Agreements will terminate upon certain circumstances, including upon termination of the Purchase Agreement or if the LAVA Board votes to approve a superior proposal or a change in the recommendation of the LAVA Board with respect to certain intervening events.

     

    The second paragraph under the heading entitled “Treatment of Equity Awards in the Transactions” on page 9 of the Schedule 14D-9 is amended and supplemented as follows:

     

    The table below sets forth, for each of LAVA’s executive officers and non-employee directors holding LAVA Options as of March 1, 2024 August 14, 2025, the aggregate number of Shares subject to such In-the-Money Options and the value of cash amounts payable in respect of such In-the-Money Options at the Merger Effective Time, calculated by multiplying the excess, if applicable, of the Cash Amount over the respective per Share exercise prices of the applicable In-the-Money Options by the number of Shares subject to such In-the-Money Options (which amounts will be subject to withholding of taxes), assuming the maximum potential Cash Amount of $1.24 per Share. No amounts have been included in the table below with respect to the CVRs to be received by LAVA’s executive officers and directors in respect of their In-the-Money Options however, each LAVA executive officer and non-employee director listed below will receive one (1) CVR for each Share subject to an outstanding In-the-Money Option.

     

    ITEM 4. THE SOLICITATION OR RECOMMENDATION

     

    Item 4 of the Schedule 14D-9 is hereby amended and supplemented as follows:

     

    The third bullet under the subheading entitled “Reasons for the Recommendation of the LAVA Board” on page 25 of the Schedule 14D-9 is amended and supplemented as follows:

     

    ·Best Value. The belief of the LAVA Board that as a result of the LAVA Board’s and the Special Committee’s extensive strategic review process and negotiation of the terms of the Transaction, LAVA had obtained an offer that was Buyer’s best offer and in that it provided an Offer Consideration that, as of the date of the Purchase Agreement, represented the highest price reasonably obtainable by the Company under the circumstances, as well as maximum capital return, no financial risks and a high degree of deal certainty to the Company’s shareholders. In light of the Company’s lack of a viable standalone business plan, the LAVA Board determined dissolution to be the most likely alternative for the Company to pursue outside of the Offer and Post-Offer Reorganization. The expected value of liquidation distributions per share (as more fully described under in this Item 4 under the heading “LAVA Management Dissolution Analysis”) was therefore a more accurate measure of the Company’s value per Share than the prevailing market price per Share. The Cash Amount of $1.16 - $1.24 per Share represented a premium to the expected liquidation distributions of $1.10 per Share, and the CVRs also would allow such shareholders to potentially receive additional payments in the future.

     

    I-2

     

     

    The sixth bullet under the subheading entitled “Reasons for the Recommendation of the LAVA Board” on page 25 of the Schedule 14D-9 is amended and supplemented as follows:

     

    ·Prospects of the Company on a Standalone Basis. The LAVA Board’s After a thorough assessment of the assets, liabilities and financial condition of the Company on a standalone basis, particularly in light of the Company’s workforce reductions and wind-down of clinical trials over the course the last two years, which precipitated workforce reductions, the LAVA Board concluded that the Company did not have a viable standalone business plan, and that the Company’s only alternative in the absence of a sale or merger would be to pursue a dissolution and liquidation of the Company;

     

    The section entitled “Dissolution Analysis” on page 29 of the Schedule 14D-9 is supplemented by adding the following language as the final paragraph of such section:

     

    The dissolution analysis included in this Schedule 14D-9 has been prepared by, and is the responsibility of, LAVA’s management. PricewaterhouseCoopers N.V. has not audited, reviewed, examined, compiled nor applied agreed-upon procedures with respect to the accompanying dissolution analysis  prospective financial information and, accordingly, PricewaterhouseCoopers N.V.  does not express an opinion or any other form of assurance with respect thereto.

     

    The third paragraph under the heading entitled “Opinion of Leerink Partners LLC” on page 30 of the Schedule 14D-9 is amended and supplemented as follows:

     

    The full text of the written opinion of Leerink Partners, dated August 3, 2025, which describes the assumptions made, and the qualifications and limitations upon the review undertaken by Leerink Partners in preparing its opinion, is attached as Annex I and is incorporated herein by reference. The summary of the written opinion of Leerink Partners set forth below is qualified in its entirety by the full text of the written opinion attached hereto as Annex I. Although the written opinion of Leerink Partners attached hereto as Annex I and the summary set forth below do not purport to describe all work performed and information considered by Leerink Partners, all material studies and analyses performed by Leerink Partners are described herein. Leerink Partners’ financial advisory services and opinion were provided for the information and assistance of the LAVA Board (in their capacity as directors and not in any other capacity) in connection with and for purposes of the LAVA Board’s consideration of the Transaction and the opinion of Leerink Partners addressed only the fairness, from a financial point of view, as of the date thereof, to the holders of Shares of the Cash Amount proposed to be paid to such holders pursuant to the terms of the Purchase Agreement. The opinion of Leerink Partners did not address any other term or aspect of the Purchase Agreement or the Transaction and does not constitute a recommendation to any stockholder of LAVA as to whether or not such holder should tender Shares in connection with the Offer, or how such stockholder should vote (if applicable) with respect to the Transaction or otherwise act with respect to the Transaction or any other matter:”

     

    I-3

     

     

    SIGNATURE

     

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:       September 3, 2025

     

      LAVA Therapeutics, N.V.
         
      By: /s/ Stephen Hurly  
        Stephen Hurly
        Chief Executive Officer and President

     

    I-4

     

    Get the next $LVTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LVTX

    DatePrice TargetRatingAnalyst
    12/12/2024$11.00 → $2.00Outperform → Market Perform
    Leerink Partners
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    10/25/2022$9.00Buy
    H.C. Wainwright
    11/16/2021$24.00 → $20.00Outperform
    SVB Leerink
    8/17/2021$26.00 → $24.00Outperform
    SVB Leerink
    More analyst ratings

    $LVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Cooperatieve Gilde Healthcare Iv U.A. claimed ownership of 5,421,170 shares (SEC Form 3)

    3 - LAVA Therapeutics NV (0001840748) (Issuer)

    4/8/25 6:19:03 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wilson Karen J

    4 - LAVA Therapeutics NV (0001840748) (Issuer)

    2/18/25 8:15:24 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kiener Peter A

    4 - LAVA Therapeutics NV (0001840748) (Issuer)

    2/18/25 8:15:17 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    SEC Filings

    View All

    Amendment: SEC Form SC TO-T/A filed by LAVA Therapeutics N.V.

    SC TO-T/A - LAVA Therapeutics NV (0001840748) (Subject)

    9/9/25 4:07:29 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 14D9/A filed by LAVA Therapeutics N.V.

    SC 14D9/A - LAVA Therapeutics NV (0001840748) (Subject)

    9/3/25 5:22:27 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFM14A filed by LAVA Therapeutics N.V.

    DEFM14A - LAVA Therapeutics NV (0001840748) (Filer)

    9/3/25 5:17:56 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA's two partnered assets and unpartnered programsConsummation of acquisition expected to occur in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholdersAnnounced decision to discontinue development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome; wind-down of the program has been initiated UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or the "Company")), a clin

    8/13/25 4:55:00 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur

    8/4/25 7:30:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

    Focused on evaluation of strategic alternatives, with restructuring and closure of the Netherlands operationsEnrollment in LAVA-1266 Phase 1 continues to progressCash, cash equivalents and short-term investments of $66.6 million as of March 31, 2025 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, May 14, 2025 (GLOBE NEWSWIRE) --  LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the first quarter ended March 31, 2025. "LAVA's top priority remains deliverin

    5/14/25 7:30:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LAVA Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously

    12/12/24 8:11:38 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics downgraded by JMP Securities

    JMP Securities downgraded LAVA Therapeutics from Mkt Outperform to Mkt Perform

    12/11/24 7:55:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on LAVA Therapeutics with a new price target

    H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00

    10/25/22 6:28:17 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Financials

    Live finance-specific insights

    View All

    XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur

    8/4/25 7:30:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria

    6/1/22 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    3/7/24 7:09:56 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)

    2/14/24 4:26:22 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

    SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

    11/9/23 4:37:57 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LVTX
    Leadership Updates

    Live Leadership Updates

    View All

    LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

    UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca

    3/9/23 8:05:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

    UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi

    2/6/23 7:00:00 AM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

    LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas

    11/16/22 4:05:00 PM ET
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care